614 results on '"Docherty, Kieran F."'
Search Results
2. Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
3. Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction: Insights From REVIVED-BCIS2
4. Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA
5. Recent successes in heart failure treatment
6. Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?
7. Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure
8. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
9. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
10. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
11. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
12. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
13. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
14. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF
15. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
16. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial
17. Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design
18. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
19. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF
20. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
21. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial
22. Sodium–glucose co-transporter-2 inhibitors
23. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
24. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
25. Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction.
26. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
27. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
28. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
29. Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers
30. Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus
31. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
32. Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction
33. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
34. Estimating the Lifetime Benefits of Treatments for Heart Failure
35. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
36. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF
37. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
38. Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure
39. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials
40. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
41. Acute heart failure: early pharmacological therapy
42. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
43. Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes
44. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial
45. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
46. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
47. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
48. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
49. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies
50. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.